ストックスクリーナーアプリを入手
4.79
12.44%
0.53
アフターアワーズ：
4.79
前日終値:
$4.26
開ける：
$4.2
24時間の取引高:
58,151
Relative Volume:
1.43
時価総額：
$6.37M
収益：
$61,000
当期純損益:
$-5.46M
株価収益率:
-0.7324
EPS:
-6.54
ネットキャッシュフロー:
$-6.76M
1週間 パフォーマンス:
+13.91%
1か月 パフォーマンス:
+20.96%
6か月 パフォーマンス:
+35.69%
1年 パフォーマンス:
-9.11%
1日の値動き範囲:
$4.1525
$4.79
1週間の範囲:
$4.03
$4.79
52週間の値動き範囲:
$3.03
$5.76
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
名前
Titan Pharmaceuticals Inc De
セクター
電話
(650) 244-4990
住所
400 OYSTER POINT BLVD, SAN FRANCISCO
TTNP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
4.79 | 5.67M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-06-26 | 開始されました | Maxim Group | Buy |
| 2017-11-10 | ダウングレード | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De (TTNP) 最新ニュース
Can Titan International Inc. (DE) stock stage a strong rebound this quarter2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2025-09-20 18:22:22 - newser.com
Real time scanner hits for Titan Pharmaceuticals Inc. explained2025 Geopolitical Influence & Accurate Buy Signal Alerts - newser.com
Automated trading signals detected on Titan Pharmaceuticals Inc.Market Risk Analysis & Pattern Based Trade Signal System - newser.com
$17.25M IPO Complete: Biotech Curanex Pharmaceuticals Secures Full Over-Allotment Exercise at $4/Share - Stock Titan
$288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs - Stock Titan
$6M Funded Breakthrough: Lobe Sciences Unveils Revolutionary Psilocin Treatment for Chronic Cluster Headaches - Stock Titan
$251 Million Capital Raise: Dianthus Therapeutics Secures Major Funding for Autoimmune Drug Development - Stock Titan
Global Pharma Leader and Sinclair Pharma Co-Founder Joins Lobe Sciences' Board of Directors - Stock Titan
Targeting 10,000 Patients by 2026: HOPE Therapeutics Acquires Dura Medical in Florida Mental Health Expansion - Stock Titan
Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan
Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan
Major Pharma Merger Advances: Semnur Pharmaceuticals-Denali Capital Deal Gets Shareholder Green Light - Stock Titan
Biotech Acurx Pharmaceuticals Secures Future on Nasdaq by Meeting Critical $1 Bid, $2.5M Equity Rules - Stock Titan
Is Titan Pharmaceuticals Inc. trending in predictive chart models2025 Biggest Moves & Verified Entry Point Signals - Newser
90% Treatment Response Target: NRx's HOPE Clinics to Revolutionize Depression & PTSD Care with Triple Therapy - Stock Titan
Using Python tools to backtest Titan Pharmaceuticals Inc. strategiesJuly 2025 Short Interest & Weekly Top Performers Watchlists - Newser
Neuroscience Biotech Xenon Pharmaceuticals Awards $2.1M in Stock Options to Expand Drug Development Team - Stock Titan
$30M Stock Offering: Cognition Therapeutics Advances Phase 3 Programs for Neurodegenerative Drug - Stock Titan
$15 Million IPO: Inflammatory Disease Biotech Curanex Launches on Nasdaq with Botanical Drug Focus - Stock Titan
Titan Pharmaceuticals Stock Surges 23% After Hours on Stockholder Approval of Three-Way Merger - Benzinga
$15 Million IPO: Botanical Drug Developer Curanex Lists on Nasdaq to Advance Ulcerative Colitis Treatment - Stock Titan
$80 Million Cash Distribution: ESSA Pharma Corrects Due Bill Trading Period Ahead of XenoTherapeutics Deal - Stock Titan
Sector ETF performance correlation with Titan Pharmaceuticals Inc.2025 Price Targets & AI Optimized Trading Strategy Guides - Newser
Will a bounce in CEMEX S.A.B. de C.V. Depositary Receipt offer an exitJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - Newser
13M Patient Market: NRx Pharmaceuticals Secures Major FDA Fast Track Win for Revolutionary Depression Drug - Stock Titan
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 304.7% in July - Defense World
Elite Pharmaceuticals Revenue More Than Doubles as New ADHD Drug Launch Drives Record Growth - Stock Titan
How Titan Pharmaceuticals Inc. stock performs during market volatilityMarket Growth Summary & Expert Curated Trade Ideas - Newser
Sonoma's First Major Consumer Product Hits Walmart Shelves: New Tech-Based Diaper Rash Treatment - Stock Titan
Ketamir-2 outperforms ketamine, plans Phase 2a FDA submission in Q4 2025 - Stock Titan
X4 Pharmaceuticals Overhauls Leadership: $60M Deal Brings CTI BioPharma's $1.7B Exit Team Onboard - Stock Titan
CVKD Files 8-K; Exhibit 99.1 Contains Q2 2025 Financials - Stock Titan
FDA Fast Track Breakthrough: NRX-100 Shows 63% Success Rate in Suicidal Depression Treatment - Stock Titan
Will earnings trigger a reversal in Titan Pharmaceuticals Inc.Daily Swing Candidate Analysis with Chart Patterns - Newser
Best Pharmaceutical Stocks to Buy in 2025 - The Motley Fool
Elite Pharmaceuticals Earnings Call: Key Corporate Updates and Q1 2026 Results Coming August 15 - Stock Titan
NRx Secures Florida Approval to Acquire Veterans Mental Health Provider Dura Medical - Stock Titan
Kiora's Q2 Earnings Reveal Dual Phase 2 Trials Progress and $110M Asia Partnership Opportunity - Stock Titan
PLBY regains Nasdaq compliance with new independent director appointment | PCSA SEC FilingForm 8-K - Stock Titan
Biotech Pioneer Processa Pharmaceuticals Embraces Crypto: Strategic Investment Meets Blockchain Innovation - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
RIGL files S-8 to register 825,000 shares for employee equity plans | RIGL SEC FilingForm S-8 - Stock Titan
Verrica Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Dermatology Pipeline - Stock Titan
TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc.TTNP - FinancialContent
Cumberland Pharmaceuticals Hits 23% Revenue Growth as DMD Drug Shows Major Heart Benefits - Stock Titan
Nuvectis Reports Clinical Trial Success: NXP900 Cancer Drug Advances as Cash Position Strengthens to $39M - Stock Titan
Biotech Terns Pharmaceuticals Appoints Chief People Officer, Awards Massive 500,000 Share Option Package - Stock Titan
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
Pharmaceutical Pioneer Artelo Makes History: Raises $9.5M to Build First-Ever Solana Treasury Strategy - Stock Titan
Titan Pharmaceuticals Inc De (TTNP) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):